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Abstract: Postoperative ileus (POI) occurs frequently in patients undergoing major abdominal 
surgery; and only recently has there been renewed interest in understanding the pathogenesis, 
etiology, clinical manifestations, and clinical and economic consequences related to POI. This 
interest has been spurred by the potential access to novel pharmaceutical options for the manage-
ment of POI. POI has a complex and multimodal pathophysiology including neurogenic, inflam-
matory, hormonal, and pharmacologic components. The clinical manifestations are   clinically 
obvious and include abdominal distention, pain, nausea, vomiting, and inability to pass stools 
or tolerate a solid diet. Prolonged ileus has been defined as persistence of these symptoms for 
more than 4 days after major abdominal surgery; however the goal should be to reduce the 
incidence of these symptoms immediately after surgery. Clearly, the magnitude of the surgical 
stress and usage of opioid analgesia are the predominant causes of POI. The unappreciated 
sequelae of POI include increased rates in adverse surgical wound healing, reduced ambulation, 
atelectasis, pneumonia, urinary infections, and deep vein thrombosis. The secondary impact 
of these complications includes increased hospital length of stay, resource use, and healthcare 
costs. POI is common and the impact is underestimated. The addition of alvimopan as the first 
in class µ-opioid inhibitor has demonstrated consistent benefit in reducing the incidence and 
impact of POI with reductions in length of hospital stay. POI is a common, and underappreci-
ated complication of major abdominal surgery, and clinicians should be aware of the clinical 
care options, including novel pharmaceutical agents, that can successfully reduce the incidence 
of this postoperative complication.
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Introduction
Postoperative ileus (POI) is perceived as an unavoidable outcome of major abdominal 
surgery, primarily due to poorly understood multifactorial pathophysiology.1 POI 
is multifactorial in origin and causative factors include neurogenic, inflammatory, 
hormonal and pharmacologic influences.1 The neurogenic component relates to the 
pain induced neural reflexes which in turn result in sympathetic hyperactivity and 
inhibition of gastrointestinal (GI) motility.2,3 Surgical manipulation contributes further 
by activating a number of inflammatory cascades, primarily via the arachidonic acid 
cascade. These mediators cause the release of endogenous opioid peptides which further 
exacerbate the effects of exogenous opioid analgesics (administered for analgesia) on 
inhibition of bowel function.4–6 The hormonal influence on ileus is primarily mediated 
via corticotropin-releasing hormone as a response to the tissue trauma.7 POI may also 
occur following minimally invasive surgical procedures, despite obvious reductions in 
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surgical trauma and manipulation of the bowel, possibly due 
to the effects of opioid analgesics mediated by stimulation of 
GI opioid receptors by exogenous opioids.8,9 The opioid nega-
tive effect on GI motility is believed to occur due to stimula-
tion of µ-opioid receptors in the bowel, leading to inertia in 
the gut.1,2 Relief of POI-related pain is a two edged sword 
as the surgeon balances adequate analgesia with additional 
impairment of GI motility. However the recent availability of 
alvimopan, a first in class oral µ-opioid receptor antagonist, 
offers the potential of effective prophylaxis against postop-
erative ileus. POI is not life-threatening, but patients with 
POI typically experience substantial discomfort.10
Ileus after abdominal surgery can last a long time despite 
the use of what is referred to as a fast-track protocol, with 
early ambulation and gradual resumption of oral intake of 
liquids followed by solid food to accelerate a return to normal 
GI function.10,11 In 149 patients undergoing major abdominal 
surgery who were encouraged to ambulate and take oral liq-
uids on the first postoperative day and eat solid food on the 
second postoperative day, more than 4 days elapsed before GI 
function returned to normal in half of the patients and 25% of 
patients had not regained normal GI function after more than 
6 days had elapsed.10 Opioid analgesic use for postoperative 
pain has been shown to correlate with the time to return of 
normal bowel function after surgery.3
Consequences
Although not life-threatening, POI can prolong postopera-
tive recovery, increase hospital length of stay and healthcare 
resource utilization and costs.12–15 The resultant abdominal 
distention increases the risk of hernia formation and wound 
dehiscence, while nausea and vomiting impacts resumption 
of enteral nutrition and increases the risk for malnutrition and 
impaired wound healing. The need for nasogastric decom-
pression and prolonged venous access inhibit ambulation 
which may increase rates of pulmonary complications and 
thromboembolus. The morbidities associated with POI and 
the added care required places greater economic burdens 
on the healthcare system. The prolonged hospitalization 
associated with POI is an important issue at hospitals with 
a limited number of beds and high demand for inpatient 
services. Efforts to minimize POI and hospital lengths of 
stay without increasing the risk of post-discharge readmis-
sion have the potential to improve the financial bottom line 
for hospitals, private and governmental health insurers, and 
society at large. Approximately 161,000 Medicare recipients 
undergo major intestinal or rectal resection each year which 
consumes an estimated 1.8 million hospital days at a cost of 
$1.75 billion.16,17 Safely shortening this length of stay would 
produce significant dividends.
Role of enhanced recovery 
programs
A multi-modal approach has been developed to improve post-
operative morbidity, including POI, in surgical patients.11,17,18 
Patient education is an important component of fast-track 
protocols to accelerate recovery of normal GI function and 
should include an understanding of how important attempt-
ing early ambulation and early enteral nutrition is to the 
care plan. They should also understand the components of 
effective pain with both narcotic and non-steroidal combina-
tions of oral medications. The newly available peripherally 
selective µ-opioid receptor antagonist alvimopan offers an 
additional adjunct to the minimization of POI rates.10
Potential role of alvimopan
A recent pooled analysis of 3 of the prospective, random-
ized and blinded alvimopan trials confirmed that a 12 mg 
dose provided optimal reduction in GI morbidity and return 
of GI function.19 These benefits are clinically relevant and 
important to clinicians when arranging discharge plans.20 An 
interesting additional benefit of alvimopan was a significant 
decrease in the incidence of POI as a serious adverse event 
coupled with a reduction in the proportion of patients who 
had prolonged hospital stay or readmission.19 These benefits 
translated into a 50% reduction in the proportion of patients 
defined as having prolonged hospital stay.
Alvimopan has been generally well tolerated in the 
  available trials without producing a negative impact on nar-
cotic analgesic effects as demonstrated by pain scores. These 
trials all included a program of early oral nutrition and ambu-
lation and therefore the reduction in time to discharge order 
written compared to placebo confirmed the additional benefit 
of alvimopan even in an enhanced recovery program.
Conclusion
The clinical and economic consequences of POI are   substantial. 
Ensuring that patients undergoing major   abdominal surgery 
understand the preoperative and   postoperative care regimen 
can minimize these consequences.
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